These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1534662)

  • 21. Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression.
    Fekkes D; Timmerman L; Pepplinkhuizen L
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):235-9. PubMed ID: 9213084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats.
    de Paula Soares V; Zangrossi H
    Behav Brain Res; 2009 Jan; 197(1):178-85. PubMed ID: 18801389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression.
    Tanay VM; Greenshaw AJ; Baker GB; Bateson AN
    Mol Psychiatry; 2001 Jul; 6(4):404-12. PubMed ID: 11443524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.
    Zwanzger P; Eser D; Nothdurfter C; Baghai TC; Möller HJ; Padberg F; Rupprecht R
    Pharmacopsychiatry; 2009 Nov; 42(6):266-9. PubMed ID: 19924586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine.
    Mortimore C; Anderson IM
    Psychopharmacology (Berl); 2000 Apr; 149(3):251-8. PubMed ID: 10823406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of single doses of pindolol and d-fenfluramine on flumazenil-induced anxiety in panic disorder patients.
    Bernik M; Ramos RT; Hetem LAB; Graeff F
    Behav Brain Res; 2019 Jan; 357-358():82-87. PubMed ID: 29113874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactate-induced panic attacks: possible involvement of serotonin reuptake stimulation.
    Lingjaerde O
    Acta Psychiatr Scand; 1985 Aug; 72(2):206-8. PubMed ID: 4050513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comment on Esler et al. (2007) "Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor".
    Hussain HM; Butt MU
    Stress; 2008 Mar; 11(2):83-4. PubMed ID: 18311598
    [No Abstract]   [Full Text] [Related]  

  • 29. Serotonin in affective disorders.
    Grahame-Smith DG
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():5-13. PubMed ID: 1431011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 5-HT7 receptor and disorders of the nervous system: an overview.
    Hedlund PB
    Psychopharmacology (Berl); 2009 Oct; 206(3):345-54. PubMed ID: 19649616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neuroanatomy of 5-HT dysregulation and panic disorder.
    Grove G; Coplan JD; Hollander E
    J Neuropsychiatry Clin Neurosci; 1997; 9(2):198-207. PubMed ID: 9144099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonergic agents in the treatment of disorders of anxiety and impulse control.
    Eriksson E
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():533A-534A. PubMed ID: 1498937
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?
    Corchs F; Nutt DJ; Hince DA; Davies SJ; Bernik M; Hood SD
    J Psychopharmacol; 2015 Oct; 29(10):1061-9. PubMed ID: 26187054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin receptors in depression and anxiety: Insights from animal studies.
    Żmudzka E; Sałaciak K; Sapa J; Pytka K
    Life Sci; 2018 Oct; 210():106-124. PubMed ID: 30144453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion.
    Anderson IM; Mortimore C
    Adv Exp Med Biol; 1999; 467():43-55. PubMed ID: 10721037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental public speaking: contributions to the understanding of the serotonergic modulation of fear.
    Garcia-Leal C; Graeff FG; Del-Ben CM
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 3():407-17. PubMed ID: 25277282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin-mediated cyclic AMP inhibitory pathway in platelets of patients affected by panic disorder.
    Dell'Osso L; Carmassi C; Palego L; Trincavelli ML; Tuscano D; Montali M; Sbrana S; Ciapparelli A; Lucacchini A; Cassano GB; Martini C
    Neuropsychobiology; 2004; 50(1):28-36. PubMed ID: 15179017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation.
    Hood SD; Bell CJ; Argyropoulos SV; Nutt DJ
    J Psychopharmacol; 2016 Nov; 30(11):1137-1140. PubMed ID: 27329165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on central nervous system serotonin receptors in mood disorders.
    Young A; Goodwin GM
    Ann Acad Med Singap; 1991 Jan; 20(1):46-50. PubMed ID: 2029163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between two models of experimental anxiety in healthy volunteers and panic disorder patients.
    Graeff FG; Silva M; Del Ben CM; Zuardi AW; Hetem LA; Guimarães FS
    Neurosci Biobehav Rev; 2001 Dec; 25(7-8):753-9. PubMed ID: 11801299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.